A multivalent antibody assembled from different building blocks using tag/catcher systems: a case study.

Protein Eng Des Sel

Sanofi-Aventis Deutschland GmbH, R&D Large Molecules Research, Industriepark Höchst, Frankfurt am Main 65926, Germany.

Published: February 2022

AI Article Synopsis

  • The field of therapeutic antibodies, particularly bi- or multispecific antibodies, is expanding rapidly, especially for cancer treatment due to their ability to target multiple pathways.
  • Designing and creating multispecific antibodies is complex and labor-intensive, starting with generating antibodies against specific targets and then combining their binding sites, as suitable configurations are hard to predict.
  • The SpyTag-SpyCatcher technology allows for easier assembly of these multispecific antibodies by enabling separate production of tag and catcher proteins, and experiments have successfully created large multivalent antibodies containing up to seven building blocks while maintaining binding functionality.

Article Abstract

The field of therapeutic antibodies and, especially bi- or multispecific antibodies, is growing rapidly. Especially for treating cancers, multispecific antibodies are very promising, as there are multiple pathways involved and multispecific antibodies offer the possibility to interfere at two or more sites. Besides being used as therapeutic, multispecific antibodies can be helpful tools in basic research. However, the design and choice of the most appropriate multispecific antibody format are far from trivial. The generation of multispecific antibodies starts with the generation of antibodies directed against the desired targets and then combining the different antigen-binding sites in one molecule. This is a time-consuming and laborious approach since the most suitable geometry cannot be predicted. The SpyTag technology is based on a split-protein system, where a small peptide of said protein, the SpyTag, can bind to the remaining protein, the SpyCatcher. An irreversible isopeptide bond between the SpyTag and the SpyCatcher is formed. A related Tag-Catcher system is the SnoopTag-SnoopCatcher. These systems offer the opportunity to separately produce proteins fused to the tag-peptides and to the catcher-domains and assemble them in vitro. Our goal was to design and produce different antibody fragments, Fab domains and Fc-containing domains, with different tags and/or catchers as building blocks for the assembly of different multivalent antibodies. We have shown that large multivalent antibodies consisting of up to seven building blocks can be prepared. Binding experiments demonstrated that all binding sites in such a large molecule retained their accessibility to their corresponding antigens.

Download full-text PDF

Source
http://dx.doi.org/10.1093/protein/gzac014DOI Listing

Publication Analysis

Top Keywords

multispecific antibodies
20
building blocks
12
antibodies
9
multivalent antibodies
8
multispecific
6
multivalent antibody
4
antibody assembled
4
assembled building
4
blocks tag/catcher
4
tag/catcher systems
4

Similar Publications

Antibodies to watch in 2025.

MAbs

December 2025

Business Intelligence Research, The Antibody Society, Inc., Framingham, MA, USA.

The commercial development of antibody therapeutics is a global enterprise involving thousands of biopharmaceutical firms and supporting service organizations. To date, their combined efforts have resulted in over 200 marketed antibody therapeutics and a pipeline of nearly 1,400 investigational product candidates that are undergoing evaluation in clinical studies as treatments for a wide variety of diseases. Here, we discuss key events in antibody therapeutics development that occurred during 2024 and forecast key events related to the late-stage clinical pipeline that may occur in 2025.

View Article and Find Full Text PDF

The Emergence of Oligonucleotide Building Blocks in the Multispecific Proximity-Inducing Drug Toolbox of Destruction.

ACS Chem Biol

December 2024

Department of Chemistry & Chemical Biology, McMaster University, 1280 Main Street West, Hamilton, ONL8S 4M1, Canada.

Oligonucleotides are a rapidly emerging class of therapeutics. Their most well-known examples are informational drugs that modify gene expression by binding mRNA. Despite inducing proximity between biological machinery and mRNA when applied to modulating gene expression, oligonucleotides are not typically labeled as "proximity-inducing" in literature.

View Article and Find Full Text PDF

The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds.

BioDrugs

December 2024

Antibody Engineering Department, Genentech Inc, South San Francisco, USA.

After decades of gradual progress from conceptualization to early clinical trials (1960-2000), the therapeutic potential of bispecific antibodies (bisp Abs) is now being fully realized. Insights gained from both successful and unsuccessful trials are helping to identify which mechanisms of action, antibody formats, and targets prove most effective, and which may benefit from further refinement. While T-cell engagers remain the most commonly used class of bisp Abs, current efforts aim to increase their effectiveness by co-engaging costimulatory molecules, reducing escape mechanisms, and countering immunosuppression.

View Article and Find Full Text PDF

CAR-T cell and T cell engager therapies have demonstrated transformational efficacy against hematological malignancies, but achieving efficacy in solid tumors has been more challenging, in large part because of on-target/off-tumor toxicities and sub-optimal T cell anti-tumor cytotoxic functions. Here, we discuss engineering solutions that exploit biological properties of solid tumors to overcome these challenges. Using logic gates as a framework, we categorize the numerous approaches that leverage two inputs instead of one to achieve better cancer selectivity or efficacy in solid tumors with dual-input CAR-Ts or multi-specific TCEs.

View Article and Find Full Text PDF

[Differential discovery strategies of bispecific and multi-specific antibody drugs].

Sheng Wu Gong Cheng Xue Bao

November 2024

RemeGen Co., Ltd., Yantai 264006, Shandong, China.

Bispecific antibody drugs have enhanced efficacy and safety compared with therapeutic monoclonal antibody drugs, gradually becoming a new generation of effective therapies. With the development of genetic engineering and the maturity of the industry, increasing studies have been carried out on bispecific and multi-specific antibody drugs, and the application indications of these drugs are expanding, which lays a foundation for satisfying the clinical needs and creating clinical values. This paper provides a comprehensive review of the development stages, indications, target combinations, structural formats, and mechanisms of bispecific and multi-specific antibody drugs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!